Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

Primo Lara,Edward Mayerson,Erik Gertz,Catherine M. Tangen,Amir Goldkorn,Marta D. Van Loan,Maha Hussain,Shilpa Gupta,Jingsong Zhang,Przemyslaw Twardowski,David I. Quinn,Nicholas J. Vogelzang,Ian M. Thompson,Neeraj Agarwal

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

2020

Primo Lara
Edward Mayerson
Erik Gertz
Catherine M. Tangen
Amir Goldkorn
Marta D. Van Loan
Maha Hussain
Shilpa Gupta
Jingsong Zhang
Przemyslaw Twardowski
David I. Quinn
Nicholas J. Vogelzang
Ian M. Thompson
Neeraj Agarwal

5523Background: We previously reported that baseline BMB are independently prognostic for overall survival (OS) in men with castration resistant prostate cancer. We correlated BMB with outcomes in ...

Keywords:

Oncology
Hormone sensitive prostate cancer
Progression-free survival
Internal medicine
Biomarker (medicine)
Bone remodeling
Pathology
Androgen deprivation therapy
Orteronel
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations